1-[3-(4-甲基苯基)-1,2,4-恶二唑-5-基]甲胺 | 890324-74-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-[3-(4-甲基苯基)-1,2,4-恶二唑-5-基]甲胺
• 中文别名: {[3-(4-甲基苯基)-1,2,4-恶二唑-5-基]甲基}胺盐酸盐
• 英文名称: C-(3-p-tolyl-[1,2,4]oxadiazol-5-yl)methylamine
• 英文别名: (3-(p-tolyl)-1,2,4-oxadiazol-5-yl)methanamine；(3-p-tolyl-1,2,4-oxadiazol-5-yl)methylamine；1-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]methanamine；[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]methanamine
• CAS: 890324-74-0
• 化学式: C₁₀H₁₁N₃O
• mdl: MFCD07087661
• 分子量: 189.217
• InChiKey: XDCYNMWXLOAGSE-UHFFFAOYSA-N

物化性质

• 沸点：
  335.3±52.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-[3-(4-甲基苯基)-1,2,4-恶二唑-5-基]甲胺 、 对甲氧基苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 以75%的产率得到4-methoxy-N-[(3-p-tolyl-1,2,4-oxadiazol-5-yl)-methyl]-benzenesulfonamide
  参考文献：
  名称：

  Synthesis, Molecular Docking, Analgesic, and Anti-Inflammatory Activities of New 1,2,4-Oxadiazolo-Sulfonamides

  摘要：

  In the present study novel 1,2,4-oxadiazolo sulfonamides 3a-3o are synthesized by an efficient method based on the reaction of 1,2,4-oxadiazole amines with aryl sulfonyl chlorides. Structures of the synthesized compounds are confirmed by IR, NMR and Mass spectra. Molecular interactions of the obtained compounds are studied by Discovery Studio v3.5, molecular docking with COX-2 enzyme. The compounds with high LibDock score are screened for their in vivo analgesic and anti inflammatory activities. The compound 3l demonstrates the highest activity.

  DOI：

  10.1134/s1070363218040278
• 作为产物：
  描述：

  (Z)-N'-(2-chloroacetoxy)-4-methylbenzimidamide 在 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 甲苯 、 乙腈 为溶剂， 反应 3.5h， 生成 1-[3-(4-甲基苯基)-1,2,4-恶二唑-5-基]甲胺
  参考文献：
  名称：

  恶二唑-异丙基酰胺作为有效的非共价蛋白酶体抑制剂

  摘要：

  对 50 000 ChemBridge 化合物库的筛选导致鉴定出恶二唑-异丙基酰胺1 (PI-1833)，其抑制胰凝乳蛋白酶样 (CT-L) 活性（IC 50 = 0.60 μM），对其他两种主要蛋白酶体几乎没有影响蛋白水解活性，胰蛋白酶样 (TL) 和谷氨酰肽水解样 (PGPH-L)。LC-MS/MS 和透析表明1是一种非共价且快速可逆的 CT-L 抑制剂。集中文库合成为11ad (PI-1840) 提供了 CT-L 活性 (IC 50= 27 纳米）。详细的 SAR 研究表明酰胺部分和两个苯环对修饰敏感。疏水性残基，如在对位丙基或丁基（未邻位或间位）的A环和一个的米-吡啶基团作为B环，显著提高活性。化合物11ad (IC 50 = 0.37 μM)在抑制完整 MDA-MB-468 人乳腺癌细胞中的 CT-L 活性和抑制其存活方面比1 (IC 50 = 3.5 μM)更有效。11ad的活

  DOI：

  10.1021/jm400221d

文献信息

• [EN] AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS<br/>[FR] DÉRIVÉS D'AZOLE EN TANT QU'INHIBITEURS DE LA VOIE WNT
  申请人：OSLO UNIVERSITY HOSPITAL HF

  公开号：WO2010139966A1

  公开（公告）日：2010-12-09

  The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

  本发明涉及公式I的新化合物，涉及其制备过程，含有这种化合物的药物配方以及它们在治疗中的应用。这些化合物在治疗和/或预防受到Wnt信号通路过度激活影响的疾病或病症中发挥特定作用。例如，它们可用于预防和/或延缓肿瘤细胞的增殖，例如结肠癌等癌症。
• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• [EN] INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY<br/>[FR] INHIBITEURS DE L'HOMOLOGUE DE SPINSTER 2 (SPNS2) À UTILISER EN THÉRAPIE
  申请人：UNIV VIRGINIA PATENT FOUNDATION

  公开号：WO2022056042A1

  公开（公告）日：2022-03-17

  The present disclosure provides SPNS2 inhibitor compounds according to Formula (I) and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.

  本公开提供了符合公式（I）的SPNS2抑制剂化合物及其药学上可接受的盐和/或互变异构体，如本公开所述，并提供了它们的药物组合物和在治疗方面使用的方法。
• Azole Derivatives as WTN Pathway Inhibitors
  申请人：Holsworth Daniel

  公开号：US20120208828A1

  公开（公告）日：2012-08-16

  The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

  本发明涉及公式I的新化合物，其制备过程，含有这些化合物的制药配方以及它们在治疗中的应用。这些化合物在防治或治疗Wnt通路信号过度激活引起的疾病或症状方面具有特殊用途。例如，它们可以用于预防和/或延缓肿瘤细胞的增殖，例如结肠癌等癌症的治疗。
• 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
  申请人：Caferro Thomas Raymond

  公开号：US08957068B2

  公开（公告）日：2015-02-17

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中R1-R6在此定义。本发明还涉及含有式（I）的化合物的组合物，并且涉及使用这种化合物来抑制具有新型活性的突变IDH蛋白质。本发明还涉及使用式（I）的化合物来治疗与这种突变IDH蛋白质相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。